Oncolytic viruses as therapeutic cancer vaccines

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Oncolytic viruses (OVs) are engineered or naturally occurring viruses that selectively infect and lyse cancer cells.
• OVs exhibit multi-mechanistic antitumor effects, including direct oncolysis, tumor vasculature targeting, and bystander effects.
• OVs induce immunogenic cell death (ICD) and autophagy, which are crucial for presenting tumor antigens and activating adaptive immunity.

Purpose of the Study:

• To explore the potential of oncolytic viruses (OVs) as cancer vaccines.
• To review strategies for enhancing OV efficacy through genetic engineering and combination therapies.
• To highlight the role of OVs in stimulating robust antitumor immune responses.

Main Methods:

• Review of existing literature on oncolytic virus therapy.
• Analysis of OV mechanisms, including direct cell killing, immune stimulation, and antigen presentation.
• Evaluation of combination strategies involving OV genetic engineering, immunotherapy, HDAC inhibitors, and cyclophosphamide.

Main Results:

• Genetically engineered OVs, particularly those armed with GM-CSF, demonstrate potent antitumor immunity in preclinical and clinical studies.
• Combination therapies, including with HDAC inhibitors and cyclophosphamide, significantly enhance OV efficacy and therapeutic index.
• OV-mediated ICD, autophagy, and immune cell modulation contribute to adaptive antitumor immunity.

Conclusions:

• Oncolytic viruses are highly promising as therapeutic cancer vaccines.
• Strategic genetic modification and rational combination therapies can further potentiate OVs for cancer treatment.
• OVs offer a multi-mechanistic approach to combat cancer by directly killing tumor cells and stimulating a potent anti-tumor immune response.